Ocrelizumab (subcutaneous) for the treatment of primary progressive or relapsing multiple sclerosis

Ocrelizumab (subcutaneous) is in clinical development for the treatment of relapsing multiple sclerosis (MS) and primary progressive MS. MS is a condition where the body's immune system mistakenly attacks the nerves in the central nervous system which consists of the brain and spinal cord. This damage prevents messages travelling from the central nervous system (CNS) to other parts of the body. It causes a range of potential symptoms from pins and needles to difficulties with balance and walking. The symptoms of MS can restrict the individual's physical activity and income-earning ability, resulting in a major financial burden on the patient and a substantial economic burden because of indirect and informal care costs, with most patients needing additional assistance in conducting daily activities, which is mostly provided by informal caregivers, such as partners or other relatives.